Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.

World Journal of Gastroenterology : WJG
Xiao-Jun ZhouYu-Sen Zhou

Abstract

To investigate the relationship between over-expression of urokinase plasminogen activator (uPA) and hepatitis B virus (HBV) related liver diseases in a transgenic mouse model. Albumin-tetracycline reverse transcriptional activator and tetO-uPA transgenic mice were generated respectively through pronuclear injection and crossed to produce the double transgenic in-alb-uPA mice, for which doxycycline (Dox)-inducible and liver-specific over-expression of uPA can be achieved. Hydrodynamic transfection of plasmid adeno-associated virus (AAV)-1.3 HBV was performed through the tail veins of the Dox-induced in-alb-uPA mice. Expression of uPA and HBV antigens were analyzed through double-staining immunohistochemical assay. Cytokine production was detected by enzyme linked immunosorbent assay and α-fetoprotein (AFP) mRNA level was evaluated through real-time quantitative polymerase chain reaction. Plasmid AAV-1.3 HBV hydrodynamic transfection in Dox-induced transgenic mice not only resulted in severe liver injury with hepatocarcinoma-like histological changes and hepatic AFP production, but also showed an increased serum level of HBV antigens and cytokines like interleukin-6 and tumor necrosis factor-α, compared with the control group. O...Continue Reading

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Gossen, H Bujard
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y ShiE Derman
Jan 1, 1995·Annual Review of Immunology·F V Chisari, C Ferrari
Dec 1, 1993·The Journal of Allergy and Clinical Immunology·A al-WabelS Raziuddin
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·A KistnerH Bujard
May 26, 1999·Journal of the National Cancer Institute·R W StephensN Brünner
Nov 30, 1999·Journal of Pediatric Gastroenterology and Nutrition·H Y HsuP I Lee
Aug 2, 2001·Nature Medicine·D F MercerN M Kneteman
Jan 29, 2002·Human Gene Therapy·Stefania LamartinaCarlo Toniatti
Aug 20, 2002·Nature Genetics·Anders H LundMaarten van Lohuizen
Aug 31, 2002·Journal of Gastroenterology·Yasuhiro Takikawa, Kazuyuki Suzuki
Sep 21, 2002·Seminars in Cell & Developmental Biology·Chris AlbaneseRichard G Pestell
Jul 28, 2004·Trends in Immunology·Anna Mondino, Francesco Blasi
Nov 11, 2006·Proceedings of the National Academy of Sciences of the United States of America·Li-Rung HuangDing-Shinn Chen
Apr 11, 2007·Biotechnology and Bioengineering·Vasily N Dobrovolsky, Robert H Heflich
Jun 29, 2007·Journal of Medical Virology·Evelyn ErnstJens Encke
May 7, 2008·Journal of Hepatology·Heidi BarthThomas F Baumert
Oct 9, 2008·Biochemical and Biophysical Research Communications·Hiroshi SuemizuMasato Nakamura
Apr 28, 2009·Advanced Drug Delivery Reviews·Knut StiegerFabienne Rolling

❮ Previous
Next ❯

Citations

Nov 28, 2013·Hepatitis Monthly·Hanping LiuJinyang He
Dec 29, 2018·G3 : Genes - Genomes - Genetics·Yu-Shan LiFeng-Chao Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

© 2021 Meta ULC. All rights reserved